Cost-Utility and Cost-Effectiveness of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

By Charmi Patel

June 20, 2024

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to various debilitating symptoms. The economic burden of MS is significant, with Disease-modifying drugs (DMDs) constituting a major portion of healthcare costs. The cost-effectiveness and cost-utility of DMDs for relapsing-remitting multiple sclerosis (RRMS) is the focus of this systematic study.

Key Findings

First-Line Treatments: Studies reveal the cost-effectiveness of various DMDs such as dimethyl fumarate, natalizumab, ozanimod, interferon beta-1a, ocrelizumab, ofatumumab, and teriflunomide. These medications show incremental cost-effectiveness ratios (ICERs) ranging from $13,110/QALY to $48,000/QALY, offering improved outcomes and higher Quality-Adjusted Life Years (QALYs) for RRMS patients.

Second-Line Treatments: Noteworthy findings include the cost-effectiveness of ofatumumab and alemtuzumab, with ICERs of $24,189/QALY and $32,000/QALY, respectively. These treatments demonstrate superior outcomes and higher QALYs compared to other DMDs. Ocrelizumab emerges as a beneficial treatment option for RRMS patients, with an ICER of $166,338/QALY.

Third-Line Treatments: Studies on highly active RRMS (HDA) patients indicate the cost-effectiveness of cladribine tablets over alemtuzumab, fingolimod, and natalizumab, with ICERs ranging from $20,000/QALY to $40,000/QALY. Cladribine tablets are identified as a dominant and cost-effective treatment for HDA patients.

DMDs in Highly Active RRMS Patients: Natalizumab is highlighted as a cost-effective treatment choice for highly active RRMS patients, offering improved outcomes and higher QALYs with an ICER of $30,000/QALY compared to other DMDs.

DMDs in Secondary Progressive MS (SPMS): Siponimod is identified as a cost-effective treatment option for SPMS patients, providing greater QALYs and Years of Life (YLs) with an ICER of $25,000/QALY compared to other DMDs.

Rituximab Analysis: Studies on rituximab reveal lower costs and higher QALYs in MS patients compared to natalizumab, with an ICER of $35,000/QALY. Rituximab emerges as a promising treatment option for MS management.

Conclusion

The review points out how crucial it is to treat RRMS with DMDs that are both helpful and affordable. Cladribine tablets, natalizumab, alemtuzumab, and siponimod emerged as optimal choices for different subsets of MS patients. Oral DMDs were favoured over injectable and intravenous options due to their convenience and cost-effectiveness. Care-oriented strategies like Best Supportive Care (BSC) and Symptom Management (SM) were recommended over drug-focused approaches for RRMS treatment.

Recommendations

Healthcare policymakers, neurologists, and stakeholders should consider the local context and cost-effectiveness data when making decisions about MS treatment strategies. Further research is needed to explore the long-term effectiveness and cost implications of different DMDs across diverse healthcare settings.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.